OP 687

Drug Profile

OP 687

Alternative Names: OP687

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Outpost Medicine
  • Class Irritable bowel syndrome therapies; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Irritable bowel syndrome; Overactive bladder

Most Recent Events

  • 17 Jan 2018 The US FDA Division of Bone, Reproductive and Urologic Products and the Division of Gastroenterology and Inborn Errors Products accept the IND applications for Overactive bladder and Irritable bowel syndrome, respectively
  • 15 Nov 2017 Preclinical trials in Irritable bowel syndrome in United Kingdom (PO) (9231425; 9227177)
  • 15 Nov 2017 Preclinical trials in Irritable bowel syndrome in USA (PO) (9231425; 9227177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top